Canaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI)

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a report released on Friday,Benzinga reports. They presently have a $11.00 price target on the stock. Canaccord Genuity Group’s price target suggests a potential upside of 103.48% from the company’s current price.

Several other equities analysts also recently weighed in on TLSI. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 price target on the stock. Finally, Roth Mkm restated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Stock Down 1.7 %

Shares of TLSI stock traded down $0.09 on Friday, hitting $5.41. The company had a trading volume of 834 shares, compared to its average volume of 44,939. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42. The firm has a market cap of $164.85 million, a P/E ratio of -2.17 and a beta of 0.48. The company has a 50-day moving average price of $5.39 and a 200-day moving average price of $4.73.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, March 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). The business had revenue of $8.26 million for the quarter, compared to analysts’ expectations of $8.12 million. Equities research analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current year.

Insider Buying and Selling at TriSalus Life Sciences

In other news, insider Sean Murphy purchased 15,000 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average price of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the purchase, the insider now directly owns 182,732 shares of the company’s stock, valued at $970,306.92. The trade was a 8.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Mary T. Szela acquired 5,030 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was purchased at an average cost of $5.03 per share, for a total transaction of $25,300.90. Following the completion of the transaction, the chief executive officer now owns 439,249 shares in the company, valued at approximately $2,209,422.47. The trade was a 1.16 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 54,856 shares of company stock valued at $294,608 in the last 90 days. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Several hedge funds have recently added to or reduced their stakes in TLSI. Connective Capital Management LLC purchased a new stake in TriSalus Life Sciences in the fourth quarter valued at $140,000. Bridgeway Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after purchasing an additional 50,000 shares during the last quarter. Bank of America Corp DE boosted its position in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after purchasing an additional 178,298 shares during the period. Northern Trust Corp boosted its position in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in TriSalus Life Sciences during the 4th quarter worth approximately $67,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.